<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11655">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988506</url>
  </required_header>
  <id_info>
    <org_study_id>P130101</org_study_id>
    <secondary_id>2013-001232-22</secondary_id>
    <nct_id>NCT01988506</nct_id>
  </id_info>
  <brief_title>Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases</brief_title>
  <acronym>TRANSREG</acronym>
  <official_title>Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ILTOO Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in
      a set of 11 autoimmune and auto-inflammatory diseases, with the aim to select diseases in
      which further therapeutic development will be performed. Extensive biological- and
      immune-monitoring pre- and post-IL2 will contribute (i) to define the common or distinct
      processes responsible for the breakdown of immunological tolerance in these pathologies and
      (ii) to discover potential biomarkers of the IL2 response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol: TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological
      and clinical responses to the administration of low doses IL2 across 11 selected
      pathologies: rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus,
      psoriasis, Behcet's disease, Wegener's granulomatosis, Takayasu's disease, Crohn's disease,
      ulcerative colitis, autoimmune hepatitis, and sclerosing cholangitis.Methods: Each patient
      will receive 1MUI /day of IL2 from Day-1 to Day-5 (the induction period), and then every 2
      weeks from Day-15 to Day-180 (the maintenance period). Patients will thereafter be followed
      up for 2 months (Day-181-Day-240). For each pathology, 6 patients will be included at
      Pitié-Salpêtrière, Cochin and Saint Antoine hospitals in Paris. An interim analysis will be
      performed in each pathology group when the first six patients have received at least 3
      months of treatment. In those pathology groups in which a Treg response will be documented,
      six additional patients will be included. In total, a minimum of 66 patients and up to 132
      patients will be enrolled in this study. Primary efficacy endpoint is the Treg response at
      Day-8. Secondary endpoints are:- the Treg response during the maintenance period,- the
      changes in markers of inflammation - the clinical response, evaluated by means of global
      generic scales [Clinical Global Impression severity scale (CGI-sev) and Clinical Global
      Impression efficacy index (CGI-eff)] as well as specific clinical and biological evaluations
      for each disease, - the frequency of relapses, - the assessment of quality of life (scale
      EuroQL-5).Expected Results: TRANSREG will define which patients respond to IL2, whether per
      pathology or according to pre-treatment phenomics, allowing to guide further clinical
      development of low dose IL2 in autoimmune and auto-inflammatory diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentages of Tregs</measure>
    <time_frame>Day8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Treg percentage (percentages of Tregs within the CD4+ lymphocytes) at Day-8 after administration of low-dose of IL2 compared to baseline (Day0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Tregs</measure>
    <time_frame>Day 15, 29, 85, 183 and 240</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in Treg percentage at Day 15, 29, 85, 183 and 240 compared to baseline (Day0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP, CRP ulta sensible, PCT, Albumin, LDH, anemia</measure>
    <time_frame>Day  0, 1, 8, 15, 29, 85, 183 and 240</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in levels of inflammation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses</measure>
    <time_frame>up to Day240</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-sev and CGI-eff scales</measure>
    <time_frame>Day 85, 183 and 240</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the clinical global impression severity and efficacy scale (CGI-sev and scale, CGI-eff scales) at Day 85, 183 and 240 compared to baseline (Day1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQL-5 scale</measure>
    <time_frame>Day 183</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the quality of life (EuroQL-5 scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of clinical, biological or radiological criteria specific to each disease</measure>
    <time_frame>up to Day 240</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in disease-specific score and/or evolution of clinical, biological or radiological criteria specific to each disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>up to Day 240</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety Assessment all along the observation period (Day-1 to Day-240): Safety assessment will include vital signs, adverse events and concomitant medications collection as well as biology during the 6 months of the treatment period; .In addition, the evolution of the disease will be followed 2 months after IL2- treatment stop.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Psoriasis</condition>
  <condition>Behcet's Disease</condition>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Takayasu's Disease</condition>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Autoimmune Hepatitis</condition>
  <condition>Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Interleukin 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interleukin 2, 1MUI.= Proleukin®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin 2</intervention_name>
    <description>Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days for 6 months</description>
    <arm_group_label>Interleukin 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 year

          -  male or female

          -  documented diagnosis of one AIID among the 11 diseases selected (following consensual
             specific criteria)

          -  stable or moderately active disease  under standard  treatment (≥ 2 months) at the
             time of inclusion,

          -  normal thyroid function (with or without treatment)

          -  effective contraception for more than two weeks at inclusion and negative beta HCG
             test for women of childbearing potential,

          -  affiliated to the social security system

          -  written informed consent form.

        Exclusion Criteria:

          -  known intolerance for IL2 (see SPC),

          -  administration of a non-authorized treatment and/or IV bolus of corticosteroids in
             the last 2 months,

          -  vaccination with live attenuated virus in the months preceding the inclusion or
             planned during the study

          -  other severe or progressive autoimmune/inflammatory pathology,

          -  low white blood cell count&lt;2000/mm3, lymphocytes &lt;600/mm3, platelets &lt;100 000/mm3,

          -  heart failure (≥ grade III NYHA), renal insufficiency (Cockcroft&lt; 60ml/mn except
             patients with lupus or Wegener's granulomatosis) or hepatic insufficiency
             (transaminases&gt; 5N except for patients with autoimmune hepatitis), or lung failure,

          -  significant abnormality in chest X-ray other than these linked to the diseases under
             investigation

          -  cancer or history of cancer cured for less than five years (except in situ carcinoma
             of the cervix or basocellular carcinoma)

          -  poor venous access not allowing repeated blood tests,

          -  restrictive diet or parenteral nutrition,

          -  surgery during the last 2 months or surgery planned during the study,

          -  participation in other biomedical research in the last 3 months or planned during the
             study.

          -  pregnant or lactating women,

          -  concomitant psychiatric disease or any other chronic illness or drug-abuse that could
             interfere with the ability to comply with the protocol or to give informed consent,

          -  positive HIV serology, active hepatitis B or EBV infection,

          -  patients under a measure of legal protection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David KLATZMANN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David KLATZMANN, MD, PhD</last_name>
    <phone>+33(0) 1 42 17 74 61</phone>
    <email>david.klatzmann@upmc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberta LORENZON, MD</last_name>
    <phone>+33(0) 1 42 17 74 61</phone>
    <email>rolorenzon@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Dermatologie - Hôpital COCHIN</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salim Aractingi, MD, PhD</last_name>
      <phone>+ 33 1 56 01 64 62</phone>
      <email>selim.aractingi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>ARACTINGI Selim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gastro Entérologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Beaugerie, MD, PhD</last_name>
      <phone>33 1 .49.28.31.71</phone>
      <email>laurent.beaugerie@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent BEAUGERIE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis Berenbaum, MD, PhD</last_name>
      <phone>33 1 .49.28.25.20</phone>
      <email>francis.berenbaum@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Francis. BERENBAUM, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIC - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Nicolas, MD</last_name>
      <phone>33 1 .42.17.85.33</phone>
      <email>nath.nicolas@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Nicolas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice CACOUB, MD, PhD</last_name>
      <phone>33 1 42.17.80.09</phone>
      <email>patrice.cacoub@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice CACOUB, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno FAUTREL, MD, PhD</last_name>
      <phone>33 1 .42.17.76.20</phone>
      <email>bruno.fautrel@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno FAUTREL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d' Hépato Gastro Entérologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier CHAZOUILLERES, MD, PhD</last_name>
      <phone>33 1.49.28.23.78</phone>
      <email>olivier.chazouilleres@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CHAZOUILLERES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 6, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL2,</keyword>
  <keyword>Interleukin 2,</keyword>
  <keyword>IL-2,</keyword>
  <keyword>Proleukin®</keyword>
  <keyword>Auto-immune disease</keyword>
  <keyword>Inflammatory disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Regulatory T cells,</keyword>
  <keyword>Treg</keyword>
  <keyword>Immunoregulation</keyword>
  <keyword>Immune tolerance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Wegener Granulomatosis</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
